Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

By T. Sheahan, Amy C. Sims, Rachel L. Graham, Vineet D. Menachery, Lisa E. Gralinski, J. Case, S. Leist, K. Pyrć, Joy Y. Feng, Iva Trantcheva and 13 more. Science Translational Medicine, 2017

1,505 citations recorded by the source corpus.

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses in vitro and in vivo. Antiviral gets the jump on coronaviruses Like other emerging infections, coronaviruses can jump from animal reservoirs into the human population with devastating effects, such as the SARS or MERS outbreaks. Sheahan et al. tested a small-molecule inhibitor that has shown activity against Ebola virus as a potential agent to be used to fight coronaviruses. This drug was effective against multiple types of coronaviruses in cell culture and in a mouse model of SARS and did not seem to be toxic. Given its broad activity, this antiviral could be deployed to prevent spreading of a future coronavirus outbreak, regardless of the specific virus that jumps over. Emerging viral infections are difficult to control because heterogeneous members periodically cycle in and out of humans and zoonotic hosts, complicating the development of specific antiviral therapies and vaccines. Coronaviruses (CoVs) have a proclivity to spread rapidly into new host species causing severe disease. Severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) successively emerged, causing severe epidemic respiratory disease in immunologically naïve human populations throughout the globe. Broad-spectrum therapies capable of inhibiting CoV infections would address an immediate unmet medical need and could be invaluable in the treatment of emerging and endemic CoV infections. We show that a nucleotide prodrug, GS-5734, currently in clinical development for treatment of Ebola virus disease, can inhibit SARS-CoV and MERS-CoV replication in multiple in vitro systems, including primary human airway epithelial cell cultures with submicromolar IC50 values. GS-5734 was also effective against bat CoVs, prepandemic bat CoVs, and circulating contemporary human CoV in primary human lung cells, thus demonstrating broad-spectrum anti-CoV activity. In a mouse model of SARS-CoV pathogenesis, prophylactic and early therapeutic administration of GS-5734 significantly reduced lung viral load and improved clinical signs of disease as well as respiratory function. These data provide substantive evidence that GS-5734 may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.

Subfields: Animal Science and Zoology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/02e82055c7eedb346971a9c8417f361bf4967e84

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Animal Science and Zoology

1. Ralph S. Baric
2. Jun Zheng
3. Rachel L. Graham

In Infectious Diseases

1. Jun Zheng
2. E. de Wit
3. Guangdi Li
4. V. Cheng
5. S. Ghasemi
6. Calvin J. Gordon
7. Leila Mousavizadeh
8. D. Porter

Citations in the corpus

• Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis (2018, background): “Given the large array of zoonotic strains poised for cross-species transmission, broad-based inhibitors of emerging coronavirus infections are a high priority (64).”
• Genotype and phenotype of COVID-19: Their roles in pathogenesis (2020, methodology): “At present therapy is based on identifying and developing monoclonal antibodies that are specific and effective against COVID-19 combines with remdesivir as a novel nucleotide analog prodrug that was used for the treatment of the Ebola virus disease.(17,21) To understand the rate of virus spread amo”
• Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. (2020, background): “Duration of symptoms before first dose of remdesivir, median (IQR), d 8 (5-11) 8 (5-11) 9 (6-11)”
• The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? (2020, background): “A broad-spectrum antiviral nucleotide prodrug named remdesivir presented potent efficacy for the treatment of MERS coronavirus and SARS coronavirus in preclinical studies.(15,16) There are several similarities between these viruses in their diagnosis and treatment.”
• Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV (2020, background): “074 μM for SARS-CoV and MERS-CoV, respectively, in HAE).(34) Activity against various bat coronaviruses was also demonstrated, with broad spectrum anti-coronavirus activity.”
• Structure of replicating SARS-CoV-2 polymerase (2020, background): “Remdesivir shows antiviral activity against coronaviruses in cell culture and animals 8 , inhibits coronavirus RdRp 9,10 , and is currently tested in the clinic as a drug candidate for treating COVID-19 patients [11] [12] [13] .”
• Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 (2020, background): “5: Not receiving supplemental oxygen but requiring medical care 34 (17) 21 (11)”
• Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease (2018, background): “Finally, GS-5734 is 3 to 30 times more active than GS-441524 in all of the CoVs we have tested (23).”
• Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 (2020, background): “72 Remdesivir was also shown to perturb pan-CoV RdRp function by inhibiting viral replication of SARS, MERS, and the model βcoronavirus murine hepatitis virus (MHV), even in settings with intact exonuclease proofreading activity.”
• [Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control]. (2020, background): “33, 34 As 2019-nCoV is an emerging virus, an effective treatment has not been developed for disease resulting from this virus.”
• Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) (2020, background): “069 μM) in human airway epithelial (HAE) cell, and, can inhibit MERS-CoV replication in mice [46].”
• Therapeutic options for the 2019 novel coronavirus (2019-nCoV) (2020, background): “2019-nCoV RdRp Penciclovir Inhibits RdRp Approved for HSV [2] 2019-nCoV, MERS-CoV, SARS-CoV RdRp Remdesivir (GS-5734) Terminates the non-obligate chain • Phase 3 for 2019-nCoV (NCT04252664, NCT04257656) • Phase 1 for Ebola (NCT03719586) [1,2, 9-11]”
• Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection (2020, background): “remdesivir of a wide range of coronaviruses in vitro and in vivo (7), may further indicate utility of remdesivir against the novel coronavirus 2019-nCoV emerging from Wuhan, China (26).”
• Remdesivir for the Treatment of Covid-19 — Final Report (2020, neutral): “There were 60 trial sites and 13 subsites in the United States (45 sites), Denmark (8), the United Kingdom (5), Greece (4), Germany (3), Korea (2), Mexico (2), Spain (2), Japan (1), and Singapore (1).”
• Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV (2020, background): “Remdesivir (RDV, GS-5734) is a broad-spectrum antiviral nucleotide prodrug with potent in vitro antiviral activity against a diverse panel of RNA viruses such as Ebola virus (EBOV), Marburg, MERS-CoV, SARS-CoV, respiratory syncytial virus (RSV), Nipah virus (NiV), and Hendra virus [16] [17] [18] .”